Am J Perinatol 2015; 32(02): 187-192
DOI: 10.1055/s-0034-1381721
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Labor Outcomes of Obese Patients Undergoing Induction of Labor with Misoprostol compared to Dinoprostone

Rudy S. Suidan
1  Department of Obstetrics, Gynecology, and Women's Health, Rutgers, New Jersey Medical School/University Hospital, Newark, New Jersey
,
Kaylah C. Rondon
1  Department of Obstetrics, Gynecology, and Women's Health, Rutgers, New Jersey Medical School/University Hospital, Newark, New Jersey
,
Joseph J. Apuzzio
1  Department of Obstetrics, Gynecology, and Women's Health, Rutgers, New Jersey Medical School/University Hospital, Newark, New Jersey
,
Shauna F. Williams
1  Department of Obstetrics, Gynecology, and Women's Health, Rutgers, New Jersey Medical School/University Hospital, Newark, New Jersey
› Author Affiliations
Further Information

Publication History

07 April 2014

22 April 2014

Publication Date:
10 June 2014 (online)

Abstract

Objective The aim of the article is to evaluate and compare labor outcomes in obese patients undergoing induction of labor (IOL) with misoprostol and dinoprostone.

Study Design This was a retrospective review of patients who delivered from February 1, 2008, to July 1, 2013 at our institution. All obese women who underwent IOL were identified. The rates of successful cervical ripening and cesarean delivery (CD) for patients who underwent IOL with misoprostol and dinoprostone were calculated and compared.

Results A total of 564 women met inclusion criteria; 297 (52.7%) were induced with misoprostol, and 267 (47.3%) were induced with dinoprostone. The misoprostol group had a higher successful cervical ripening rate (78.1 vs. 66.7%; odds ratio [OR], 1.79; 95% confidence interval [CI], 1.23–2.6; p = 0.002) and a lower CD rate (39.1 vs. 51.3%; OR, 0.61; 95% CI, 0.44–0.85; p = 0.003) than the dinoprostone group. This significance persisted in a multivariate model adjusting for parity, gestational age, birth weight, and indication for IOL. The rates of tachysystole, terbutaline use, postpartum hemorrhage, and infectious morbidity were comparable in both groups, as were Apgar scores, rates of neonatal intensive care unit admission, and meconium passage.

Conclusion In obese women undergoing IOL, misoprostol leads to a higher successful cervical ripening rate and a lower CD rate than dinoprostone, with a similar rate of peripartum complications and neonatal outcomes.